Fulminant Mycoplasma pneumoniae pneumonia.
- Y. Takiguchi, N. Shikama, N. Aotsuka, H. Koseki, T. Terano, A. Hirai
- Medicine, BiologyInternal medicine
- 1 April 2001
A 64-year-old woman who was previously in good health was admitted because of progressive respiratory distress and given a diagnosis of pneumonia caused by Mycoplasma pneumoniae serologically, acute respiratory distress syndrome, and disseminated intravascular coagulation died of multiple organ failure.
The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno‐occlusive disease after stem cell transplantation
The initial promising report of a prophylactic effect of UDCA on VOD after stem cell transplantation was confirmed in this prospective study, and UDCA was highly effective in preventing VOD, which occurred in only 3.0% in the UDCA‐treated group, as opposed to 18.5% inthe control group.
Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.
This study is the first to show the superiority of HDCA/CY/ TBI to CY/TBI in CBT for AML/MDS, and a large-scale prospective study is warranted to establish new conditioning regimens including HDCA administration.
Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia
Results showed that HLA matching in combination with total nucleated cell dose positively affects survival, and an increased number of mismatched HLA loci correlated with an increased risk of mortality in children and adults.
Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Secondary solid tumors after allogeneic hematopoietic SCT in Japan
The data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS.
A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of…
According to the findings, some chronic myeloid leukemia patients treated with imatinib may benefit from a switch to second-generation tyrosine kinase inhibitors (ClinicalTrials.gov, UMIN000004935).
GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia
Results suggest that MMF-containing prophylaxis may be preferable in RIC-UCBT, particularly for high-risk disease.
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
It is safe and feasible to stop tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia who have achieved a sustained deep molecular response with 2 years of treatment with nilotinib, according to the results of this study.
Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission
There were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use, and it is necessary to pay attention to KIR incomp compatibility in the HVG direction for engraftment.